Emergent Initiates Phase 1 for Potential Intranasal Treatment for Cyanide Poisoning

  Emergent BioSolutions   Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment being developed for known or suspected acute cyanide poisoning. Under an existing multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), and in collaboration with the Southwest Research Institute, Emergent is developing a single-use intranasal spray intended for administration by first responders and medical personnel following a cyanide incident.

“Emergent’s R&D efforts are grounded in our mission – to protect and enhance life,” said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions. “We are committed to advancing unique programs like SIAN, which addresses the need for an easily administered first-line treatment for cyanide poisoning. Intranasal SIAN is being developed for potential use by both civilians and first responders and is part of our portfolio of medical countermeasures focused on priority public health threats identified by the U.S. government.”

This Phase 1, open label, single ascending dose clinical study plans to enroll 70 healthy males or non-pregnant females between the ages of 18 to 45. For more information on this study, visit clinicaltrials.gov.

This study is funded by BARDA, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under contract HHSO100201700001C.

https://www.biospace.com/article/releases/emergent-biosolutions-initiates-phase-1-study-evaluating-potential-intranasal-treatment-for-cyanide-poisoning/